MedTrace Logo

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

NCT00437216 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2488

Last updated 2022-07-29

No results posted yet for this study

Summary

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Conditions

Interventions

DRUG

Clobetasol Propionate, 0.05%

Apply twice daily for 2 or 4 weeks as monotherapy

DRUG

Clobetasol propionate, 0.05% Spray

Apply twice daily for 2 or 4 weeks as add-on therapy

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Ronald W Gottschalk, MD · Galderma Laboratories, LP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437216 on ClinicalTrials.gov